



Dyeing fungi: amphotericin B based fluorescent probes for multiplexed imaging†

Cite this: *Chem. Commun.*, 2021, **57**, 1899

Received 16th December 2020,
Accepted 18th January 2021

DOI: 10.1039/d0cc08177a

rsc.li/chemcomm

Assel Baibek,^a Muhammed Üçüncü,^{ab} Bryn Short,^c Gordon Ramage,^d
Annamaria Lilienkamp^{ab} and Mark Bradley^{ab*}

The clinically used antifungal polyene amphotericin B was conjugated, via the mycosamine and the aglycon moieties, to fluorophores. The Cy5 conjugated probe showed selective labelling of fungi in the presence of bacteria, allowing multiplexed imaging and identification of microbial species in a co-culture of fungi and Gram-positive and Gram-negative bacteria.

Current diagnostic methods for infections typically involve sample collection followed by subsequent culture and microorganism detection/analysis/characterisation. However, culture-based methods are inherently slow (even for rapidly growing species) and do not allow immediate, point of care diagnostics and treatment,^{1,2} which is crucial for giving patients the correct antimicrobial agent at the right time. As a result, patients are often treated empirically with broad-spectrum antibiotics before confirmed diagnosis, which can contribute to an increase in multidrug resistance.^{3,4} Various diagnostic tests differ in their reliability, speed, complexity and cost. Widely used DNA-based tests (e.g. PCR and microarrays) are extremely sensitive; however, they are relatively complex requiring trained personnel, instrumentation, and the design of primers for the predicted pathogen, while also requiring relatively complex sample processing and as such typically take >24 h from sample to result.⁵ Access to these methods is also typically limited in rural areas in developing countries. Thus, there is an urgent need for rapid and precise diagnostic techniques.

Optical molecular imaging, using target specific fluorescent probes, could enable rapid *in vivo* detection of infection.^{6–10} Key

is the need for rationally designed fluorescent probes that can selectively and specifically detect microorganisms in complex biological scenarios, while such probes could also be applied *in vitro* as tools for the rapid diagnosis of samples such as sputum, urine, and blood. Numerous fluorescent probes have been designed and used for selective detection of Gram-positive^{11–14} and Gram-negative bacteria,^{7,15} and the detection of resistance gene products such as β -lactamases.^{16,17} However, despite the widespread incidence of fungal infections, there are only a limited number of probes for the identification of fungi.^{6,18–21}

Here, fluorescent probes for the selective detection of fungi over bacteria are reported, with fluorescent dyes conjugated at two different positions of the widely utilised antifungal agent amphotericin B (AmB), to allow investigation of the optimal position for fluorophore conjugation. Attachment of red-emitting fluorophores removed interference from background autofluorescence (a problem with green fluorescent probes)²² and demonstrated highly successful, “wash-free” labelling of clinically relevant strains of fungi, including an AmB-tolerant strain of *Candida auris* and biofilm forming fungi, as well as selectivity against both Gram-negative and positive bacteria. Importantly, an AmB-based probe, used in conjunction with two bacteria specific probes with different fluorophores, allowed multiplexed imaging of mixed cultures of microorganisms.

Amphotericin B (AmB) is a clinically used antifungal agent that disrupts the cell membrane by binding to ergosterol, a component that is specific to the fungal cell membrane. It leads to cell death by the formation of pores that allow uncontrolled ion leakage. The positively charged amino group in the mycosamine moiety of AmB has been suggested as being vital for antifungal activity as it is believed to play a key role in the interaction with ergosterol;²³ however, membrane labelling has been reported by conjugation of fluorescein to the mycosamine of AmB through a piperazinyl linker.²⁰ Thus, here both the carboxylic acid of the aglycon and the amine of the mycosamine moiety of AmB were conjugated to fluorophores *via* an amide bond to ascertain the optimal conjugation position and to

^a EaStChem School of Chemistry, The University of Edinburgh, Edinburgh, UK.
E-mail: mark.bradley@ed.ac.uk


^b Department of Analytical Chemistry, Faculty of Pharmacy, Izmir Katip Celebi University, Izmir, Turkey

^c The University of the West of Scotland, Institute of Healthcare, Policy and Practice, Paisley, UK

^d School of Medicine, Dentistry and Nursing, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

† Electronic supplementary information (ESI) available: Synthetic schemes, spectroscopic and biological data, experimental procedures and characterisation of compounds. See DOI: 10.1039/d0cc08177a





Scheme 1 Synthesis of the AmB-based probes for the fluorescent labelling of fungi. Fluorophores NBD, MeroCy and Cy5 were conjugated, via a PEG spacer, to the mycosamine and the aglycon moieties of AmB.

clarify the importance of specific functional groups of AmB. Nitrobenzofurazan (NBD, $\lambda_{\text{ex/em}} = 475/545$ nm) and the far-red emitting sulfonated merocyanine (MeroCy, $\lambda_{\text{ex/em}} = 597/627$ nm) were chosen as fluorophores as their fluorescence increases within hydrophobic environments²⁴ such as the cell membrane. Sulfonated Cy5 ($\lambda_{\text{ex/em}} = 653/671$ nm) was also explored as a means of promoting probe solubility by adding a negatively charged moiety to the probe. Two different lengths of a polyethylene glycol (PEG)-based spacer were also investigated – again, as a means of promoting solubility and to minimise the effect of the fluorophore on the labelling/binding efficiency of the AmB-conjugates (Scheme 1).

For the conjugation of the fluorophores to the mycosamine moiety of AmB, PEG functionalised NBDs **1** and **2** were synthesised (Scheme S1, ESI†) and their corresponding activated *N*-hydroxysuccinimide (NHS) esters **3** and **4** coupled to AmB to give probes **AmB-NBD-1B** and **AmB-NBD-2B** (Scheme 1). For coupling to the aglycon moiety of AmB, the carboxylic acid was activated *in situ* using PyBOP²⁵ followed by the addition of amino-PEG functionalised NBD fluorophores **7** and **8**, sulfonated MeroCy **12** or Cy5 **13** to give **AmB-NBD-1A**, **AmB-NBD-2A**, **AmB-MeroCy** and **AmB-Cy5**, respectively. The amine functionalised sulfonated MeroCy was synthesised in three steps. *N*-Alkylation of sulfonated indoline **9** with Boc-protected aminohexyl bromide gave **10** in 72% yield, which was subsequently reacted with benzothiophenone²⁴ **11** in the presence of sodium acetate (μw irradiation at 75 °C) to give the *Boc*-protected MeroCy that was deprotected under acidic conditions to give

the amino-functionalised MeroCy **12** (Scheme S3, ESI†). For the **AmB-Cy5** probe, sulfonated Cy5²⁶ was converted to the corresponding NHS-ester with HSPyU and coupled to Boc-1-amino-3,6-dioxo-8-octanediamine, followed by Boc-group cleavage to give the amino-PEG functionalised Cy5 **13** (Scheme S4, ESI†).

The AmB-NBD conjugates were incubated with *Candida albicans* (10 μM , 1 h) and the fungi imaged using confocal microscopy. **AmB-NBD-1A** and **AmB-NBD-2A** showed good labelling of the cell membrane, whereas **AmB-NBD-1B** and **AmB-NBD-2B** showed reduced labelling (Fig. 1), indicating that the aglycon moiety of AmB was the optimal site of fluorophore conjugation. Similarly, **AmB-MeroCy** (10 μM , 2 h) and **AmB-Cy5** (10 μM , 1 h) both interacted well with the fungal membrane (Fig. S2a, ESI†). **AmB-NBD-2A** and **AmB-MeroCy** showed an increase in fluorescence intensity in response to a hydrophobic environment²⁴ (Fig. S1, ESI†), while **AmB-Cy5** was the most soluble probe. Optimal labelling was observed with the red-emitting probes **AmB-MeroCy** (10 μM) and **AmB-Cy5** (10 μM) and were thus used for further studies, for example, imaging five different clinical isolates of *Candida*, including the life-threatening *C. auris* strain (Fig. 2a and Fig. S2b, S2c, ESI†). All the *Candida* strains showed comparable labelling of the fungal membrane, remarkably, *C. auris* strain NCPF 8993, which is AmB tolerant (MIC 1 $\mu\text{g mL}^{-1}$, MFC >32 $\mu\text{g mL}^{-1}$, Table S1, ESI†), was also efficiently labelled, suggesting that drug resistance does not arise from blockage of interaction of the drug with the cell membrane. In addition, considering that invasive fungal infection can be caused not only by yeast forming, but






Fig. 1 (a) Fluorescent confocal microscopy images ($\lambda_{\text{ex}} = 488 \text{ nm}$) of *C. albicans* labelled using the AmB-NBD probes. Fungi were grown in potato dextrose liquid media overnight, then incubated with the probes ($10 \mu\text{M}$ in PBS) for 1 h at 37°C . Scale bar $10 \mu\text{m}$. (b) Fluorescent intensities were quantified by single cell selection on a bright field view and measuring the mean fluorescent intensities of the raw fluorescent images (for at least 20 cells with the autofluorescence signal (no probe) subtracted). Bars show the mean fluorescence ($\pm\text{SEM}$).




Fig. 2 (a) Confocal microscopy images of clinically isolated *Candida* strains and spore-forming strains of *Aspergillus fumigatus* and *Fusarium solani* labelled with AmB-MeroCy and AmB-Cy5 ($10 \mu\text{M}$, 2 h at 37°C). See ESI,† Fig. S3 full panel of clinical strains tested. (b) Fungal biofilms of clinical isolate *C. auris* NCPF 8993 incubated with AmB-MeroCy and AmB-Cy5 ($10 \mu\text{M}$, 2 h). Scale bar $10 \mu\text{m}$.

also by spore-forming species, strains of *Aspergillus fumigatus* and *Fusarium solani* were evaluated and also showed successful labelling of the hyphae with both probes (Fig. 2a).

While testing free-floating planktonic cells provides important scientific proof of the probes' interaction with fungi, in real life infections most fungal species form and exist within

biofilms.²⁷ In biofilms, fungi aggregate and adhere to each other expressing an extracellular matrix, making it difficult for external molecules to penetrate through and interact with the fungi.^{28,29} Considering this challenge, fungal biofilms of the clinical isolate *C. auris* NCPF 8993 were generated and incubated with AmB-MeroCy and AmB-Cy5 ($10 \mu\text{M}$, 2 h), with confocal images showing uniform labelling of the fungal population within the biofilms with both probes (Fig. 2b). These results demonstrate that these AmB-based probes can be used for detection of fungi not only as planktonic cells, but in the form of aggregated biofilms.

The lack of ergosterol in the bacterial cell wall should allow the specific detection of fungi with the AmB-based probes in the presence of bacteria and, indeed, incubation of *Staphylococcus aureus* or *Escherichia coli* with AmB-Cy5 did not show any bacterial labelling (Fig. 3a). AmB-Cy5 was also used with the recently reported probe, Vancomycin-MeroCy¹⁴ (Van-MeroCy, which selectively labels Gram-positive bacteria in the presence of Gram-negative bacteria) and Polymyxin-NBD (PMX-NBD, which selectively labels Gram-negative bacteria) to demonstrate multiplexed imaging and identification in a mixed culture – in essence providing a tool for the rapid detection and distinguishing




Fig. 3 Multiplexed imaging of a fungi and bacteria. (a) *C. albicans* and a mixed culture of *S. aureus* and *E. coli* were incubated with AmB-Cy5 ($10 \mu\text{M}$) for 1 h at 37°C . The media was removed, PBS added, and the cells were imaged at $\lambda_{\text{ex}} = 633 \text{ nm}$. See ESI,† Fig. S6 for the fluorescence plot profiles. (b) Confocal microscopy images of a live co-culture of fungi (*C. albicans*) with Gram-positive bacteria (*S. aureus* in blue) and Gram-negative bacteria (*E. coli* in green). The bacteria and fungi were co-incubated for 1 h at 37°C with AmB-Cy5 ($10 \mu\text{M}$ in red) and the Gram-positive bacteria probe Van-MeroCy¹⁴ ($1 \mu\text{M}$) and Gram-negative bacteria probe PMX-NBD⁷ ($5 \mu\text{M}$). Scale bar $10 \mu\text{m}$. See also Movies 1 and 2 (ESI†). For imaging, the cells were simultaneously excited at 488 nm, 561 nm and 633 nm with emission detected in three channels using automated spectral dye separation. *Due to the spill over of signal from the MeroCy fluorophore into Cy5 channel image processing was performed by subtraction of the 'blue' signals from the 'red' using ImageJ (ESI†).



of three different types of microorganisms in a single sample. When mixed cultures of *C. albicans* and Gram-positive and Gram-negative bacteria (*S. aureus* and *E. coli*, respectively) were established and **AmB-Cy5** (10 μ M, 1 h) added, highly selective labelling of fungi was observed (Fig. 3b and Fig. S3, S5, Scheme S5, ESI[†]), with the bacterial probes **Van-MeroCy** and **PMX-NBD** enabling the selective labelling of bacteria.

In conclusion, conjugation of fluorophores to the carboxylic acid of aglycon of antifungal agent amphotericin B gave fluorescent probes that were able to efficiently label the fungal membrane, also supporting the observation that the mycosamine moiety is required for antifungal activity. Development of far-red emitting probes demonstrated efficient labelling of numerous strains of fungi, including a number of clinical isolates. Importantly, the probes also successfully labelled spore-forming fungi, as well as fungi in biofilms illustrating their versatility. Probes conjugated to the Sulfo-Cy5 fluorophore were able to selectively label fungi in the presence of both Gram-positive and Gram-negative bacteria, thus allowing multiplexed fluorescent labelling in a microbial mixture. Having this arsenal of highly selective fluorescent probes with different fluorophores will allow the rapid diagnosis of the source of infection be it bacterial or fungal in origin.

We would like to thank the Engineering and Physical Sciences Research Council (UKRI, EPSRC, UK) Interdisciplinary Research Collaboration grants EP/K03197X/1 and EP/R005257/1 for funding, and Bolashak International Scholarship for A. B., and the CALM imaging facilities at the Queens Medical Research Institute, University of Edinburgh.

Conflicts of interest

No conflicts of interest.

Notes and references

- 1 B. A. Alexander, *Transpl. Infect. Dis.*, 2002, **4**, 32–37.
- 2 D. Limmathurotsakul, K. Jamsen, A. Arayawichanon, J. A. Simpson, L. J. White, S. J. Lee, V. Wuthiekanun, N. Chantratita, A. Cheng, N. P. J. Day, C. Verzilli and S. J. Peacock, *PLoS One*, 2010, **5**, e12485.
- 3 C. E. Luyt, N. Br  chot, J.-L. Trouillet and J. Chastre, *Critical Care*, 2014, **18**, 480.
- 4 C. L. Ventola, *Pharm. Ther.*, 2015, **40**, 277–283.
- 5 M. J. Espy, J. R. Uhl, L. M. Sloan, S. P. Buckwalter, M. F. Jones, E. A. Vetter, N. L. Wengenack, J. E. Rosenblatt, F. R. Cockerill, III and T. F. Smith, *Clin. Microbiol. Rev.*, 2006, **19**, 165–256.
- 6 L. Mendive-Tapia, C. Zhao, A. R. Akram, S. Preciado, F. Albericio, M. Lee, A. Serrels, N. Kielland, N. D. Read, R. Lavilla and M. Vendrell, *Nat. Commun.*, 2016, **7**, 10940.
- 7 A. R. Akram, S. V. Chankeshwara, E. Scholefield, T. Aslam, N. McDonald, A. Megia-Fernandez, A. Marshall, B. Mills, N. Avlonitis, T. H. Craven, A. M. Smyth, D. S. Collie, C. Gray, N. Hirani, A. T. Hill, J. R. Govan, T. Walsh, C. Haslett, M. Bradley and K. Dhaliwal, *Sci. Transl. Med.*, 2018, **10**, eaal0033.
- 8 X. Ning, S. Lee, Z. Wang, D. Kim, B. Stubblefield, E. Gilbert and N. Murthy, *Nat. Mater.*, 2011, **10**, 602–607.
- 9 Y. Kong, H. Yao, H. Ren, S. Subbian, S. L. G. Cirillo, J. C. Sacchettini, J. Rao and J. D. Cirillo, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 12239.
- 10 A. R. Akram, N. Avlonitis, A. Lilienkamp, A. M. Perez-Lopez, N. McDonald, S. V. Chankeshwara, E. Scholefield, C. Haslett, M. Bradley and K. Dhaliwal, *Chem. Sci.*, 2015, **6**, 6971–6979.
- 11 M. van Oosten, T. Schafer, J. A. Gazendam, K. Ohlsen, E. Tsompanidou, M. C. de Goffau, H. J. Harmsen, L. M. Crane, E. Lim, K. P. Francis, L. Cheung, M. Olive, V. Ntziachristos, J. M. van Dijk and G. M. van Dam, *Nat. Commun.*, 2013, **4**, 2584.
- 12 H.-Y. Kwon, X. Liu, E. G. Choi, J. Y. Lee, S.-Y. Choi, J.-Y. Kim, A. Wang, S.-J. Park, B. Kim, Y.-A. Lee, J.-J. Kim, N. Y. Kang and Y.-T. Chang, *Angew. Chem., Int. Ed.*, 2019, **58**, 8426–8431.
- 13 W. Wang, Y. Zhu and X. Chen, *Biochemistry*, 2017, **56**, 3889–3893.
- 14 B. Mills, A. Megia-Fernandez, D. Norberg, S. Duncan, A. Marshall, A. R. Akram, T. Quinn, I. Young, A. M. Bruce, E. Scholefield, G. O. S. Williams, N. Krstaji  , T. R. Choudhary, H. E. Parker, M. G. Tanner, K. Harrington, H. A. C. Wood, T. A. Birks, J. C. Knight, C. Haslett, K. Dhaliwal, M. Bradley, M. Ucuncu and J. M. Stone, *Eur. J. Nucl. Med. Mol. Imaging*, 2020, DOI: 10.1007/s00259-020-05021-4.
- 15 H. L. Chan, L. Lyu, J. Aw, W. Zhang, J. Li, H.-H. Yang, H. Hayashi, S. Chiba and B. Xing, *ACS Chem. Biol.*, 2018, **13**, 1890–1896.
- 16 W. Phetsang, R. Pelingon, M. S. Butler, S. Kc, M. E. Pitt, G. Kaeslin, M. A. Cooper and M. A. T. Blaskovich, *ACS Infect. Dis.*, 2016, **2**, 688–701.
- 17 G. Zlokarnik, P. A. Negulescu, T. E. Knapp, L. Mere, N. Bures, L. Feng, M. Whitney, K. Roemer and R. Y. Tsien, *Science*, 1998, **27**, 84–88.
- 18 A. Pratt, G. Garcia-Effron, Y. Zhao, S. Park, A. Mustaev, S. Pillai and D. S. Perlin, *Med. Mycol.*, 2013, **51**, 103–107.
- 19 M. H. Lee, G. Wiedman, S. Park, A. Mustaev, Y. Zhao and D. S. Perlin, *Med. Mycol.*, 2017, **56**, 796–802.
- 20 A. Zumbuehl, D. Jeannerat, S. E. Martin, M. Sohrmann, P. Stano, T. Vigassy, D. D. Clark, S. L. Hussey, M. Peter, B. R. Peterson, E. Pretsch, P. Walde and E. M. Carreira, *Angew. Chem., Int. Ed.*, 2004, **116**, 5293–5297.
- 21 C. Zhao, A. Fernandez, N. Avlonitis, G. Vande Velde, M. Bradley, N. D. Read and M. Vendrell, *ACS Comb. Sci.*, 2016, **18**, 689–696.
- 22 M. S. Graus, A. K. Neumann and J. A. Timlin, *J. Biomed. Opt.*, 2017, **22**(1–6), 6.
- 23 M. Harsch and J. O. Lampen, *Biochem. Pharmacol.*, 1963, **12**, 875–883.
- 24 C. J. MacNevin, D. Gremyachinskiy, C.-W. Hsu, L. Li, M. Rougie, T. T. Davis and K. M. Hahn, *Bioconjugate Chem.*, 2013, **24**, 215–223.
- 25 A. N. Tevyashova, A. M. Korolev, A. S. Trenin, L. G. Dezhenskova, A. A. Shtil, V. I. Polshakov, O. Y. Savelyev and E. N. Olsufyeva, *J. Antibiot.*, 2016, **69**, 549–560.
- 26 W. Li, J. Geng, H. Titmarsh, A. Megia-Fernandez, K. Dhaliwal, M. Frame and M. Bradley, *Biomacromolecules*, 2018, **19**, 2721–2730.
- 27 R. Rajendran, L. Sherry, C. J. Nile, A. Sherriff, E. M. Johnson, M. F. Hanson, C. Williams, C. A. Munro, B. J. Jones and G. Ramage, *Clin. Microbiol. Infect.*, 2016, **22**, 87–93.
- 28 E. G. Dominguez, R. Zarnowski, H. L. Choy, M. Zhao, H. Sanchez, J. E. Nett and D. R. Andes, *mSphere*, 2019, **4**, e00680–00618.
- 29 R. Zarnowski, H. Sanchez, A. S. Covelli, E. Dominguez, A. Jaromin, J. Bernhardt, K. F. Mitchell, C. Heiss, P. Azadi, A. Mitchell and D. R. Andes, *PLoS Biol.*, 2018, **16**, e2006872.

